Autism

Neurology·MeSH: Autistic Disorder

18 drugs in development·14 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
folinic acid	GH Research PLC (GHRS)
GWP42003-P	Jazz Pharmaceuticals plc (JAZZ)
KarX-EC	BRISTOL MYERS SQUIBB CO (BMY)
nti164	Innovation Pharmaceuticals Inc. (IPIX)

Phase 2(8)

Drug	Company
Cannabidivarin	UNITED THERAPEUTICS Corp (UTHR)
dt402	Definium Therapeutics Inc. (DFTX)
dt402 (r-enantiomer of 3	Definium Therapeutics Inc. (DFTX)
gwp42006	GW PHARMACEUTICALS PLC (GWPH)
Intranasal Oxytocin	UNITED THERAPEUTICS Corp (UTHR)
ml-004/	MapLight Therapeutics, Inc. (MPLT)
MM402	Definium Therapeutics Inc. (DFTX)
pax-101	Kuvatris Therapeutics, Inc. (PXMD)

Preclinical(4)

Drug	Company
fin-211	Finch Therapeutics Group, Inc. (FNCH)
novel cannabinoid therapeutic	Greater Cannabis Company, Inc. (GCAN)
prana bio nutrient medicinals	UNITED CANNABIS CORP (CNAB)
qbm-001	Q BioMed Inc. (QBIO)

Phase 4(2)

Drug	Company
Cannabidivarin	Jazz Pharmaceuticals plc (JAZZ)
Gabapentin	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 18 drugs in development for Autism across 14 companies.

There are 7 clinical trials targeting Autism tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.